APRE · Aprea Therapeutics, Inc.
Market Cap
$10.07M
Shares
12.59M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-28 | — | |
| 10-Q | 2026-08-12 | 2026-06-30 | |
| 8-K | 2026-08-12 | — | |
| 8-K | 2026-07-23 | — | |
| 8-K | 2026-06-17 | 2026-06-16 | |
| 10-Q | 2026-05-13 | 2026-03-31 | |
| 8-K | 2026-05-13 | — | |
| DEF 14A | 2026-04-30 | 2026-06-16 | |
| 8-K | 2026-04-01 | — | |
| 8-K | 2026-03-30 | — | |
| 10-K | 2026-03-16 | 2025-12-31 | |
| 8-K | 2026-03-16 | — | |
| 8-K | 2026-02-18 | — | |
| 8-K | 2026-01-29 | 2026-01-28 | |
| 8-K | 2026-01-23 | — | |
| 8-K | 2026-01-09 | — | |
| 8-K | 2025-12-09 | 2025-12-08 | |
| 10-Q | 2025-11-12 | 2025-09-30 | |
| 8-K | 2025-11-12 | — | |
| 8-K | 2025-10-24 | — | |
| 8-K | 2025-10-15 | — | |
| 8-K | 2025-09-08 | — | |
| 10-Q | 2025-08-12 | 2025-06-30 | |
| 8-K | 2025-08-12 | — | |
| 8-K | 2025-06-09 | 2025-06-05 | |
| 10-Q | 2025-05-14 | 2025-03-31 | |
| 8-K | 2025-05-14 | — | |
| DEF 14A | 2025-04-22 | 2025-06-05 | |
| 8-K | 2025-03-25 | — | |
| 10-K | 2025-03-25 | 2024-12-31 | |
| 8-K | 2025-02-05 | — | |
| 8-K | 2025-01-13 | — | |
| 8-K | 2024-11-08 | — | |
| 8-K | 2024-11-07 | — | |
| 10-Q | 2024-11-07 | 2024-09-30 | |
| 8-K | 2024-10-23 | — | |
| 8-K | 2024-10-09 | — | |
| 8-K | 2024-08-12 | — | |
| 10-Q | 2024-08-12 | 2024-06-30 | |
| 8-K | 2024-06-20 | — | |
| 8-K | 2024-06-17 | — | |
| 8-K | 2024-05-14 | — | |
| 10-Q | 2024-05-14 | 2024-03-31 | |
| DEF 14A | 2024-04-25 | 2024-06-20 | |
| 8-K | 2024-04-10 | — | |
| 10-K | 2024-03-26 | 2023-12-31 | |
| 8-K | 2024-03-26 | — | |
| 8-K | 2024-03-12 | 2024-03-11 | |
| 8-K | 2024-02-06 | — | |
| 8-K | 2024-02-02 | — |
Showing 1–50 of 127 filings
Key facts
CIK
1781983
CUSIP
03836J201
13F (30d)
28 filings
28 filers
Visit website
Investor relations